Goldman Sachs
INBX icon

Goldman Sachs’s Inhibrx INBX Stock Holding History

Goldman Sachs’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.47M Hold
66,500
– – ﹤0.01% 3812
2025
Q4 		$5.25M Buy
+66,500
New +$4.53M ﹤0.01% 3693

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Goldman Sachs's INBX Position: Q1 2026 in Review

Goldman Sachs reduced its Inhibrx (INBX) stake by 5.5% in Q1 2026, selling an estimated $411K and leaving 95,074 shares worth $6.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3467.

Goldman Sachs first reported a position in INBX in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.95M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Goldman Sachs held 95,074 shares of Inhibrx worth $6.39M as of Q1 2026.
  • Goldman Sachs sold 5,543 Inhibrx shares in Q1 2026, an estimated $411K.
  • Inhibrx made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3467 holding.
  • Goldman Sachs first reported a position in Inhibrx in Q3 2024 and has held it in 7 quarters since.
  • Goldman Sachs's Inhibrx position peaked at $7.95M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.